Navigation Links
Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost
Date:3/27/2008

Companies with Two to Nine Employees Now Have Choices and Flexibility

Typically Available on Larger Plans

NEW YORK, March 27 /PRNewswire / -- Small business owners with two to nine employees can now choose from a wider selection of dental plan designs, comparable to the choices typically available only to larger companies.

The Guardian Life Insurance Company of America (Guardian), a leading provider of employee and voluntary benefits for small and mid-sized companies, today announced the expansion of options that enable small groups with Guardian's Dental Guard Basic and Basic Plus plans to mix and match the level of coverage for procedures such as root canals, crowns, bridges, extractions, and dentures.

"A budding technology company with primarily Gen X and Gen Y employees probably doesn't need coverage for dentures and shouldn't absorb the cost for a benefit that their employees probably won't use," said Clancy Merrill, Executive Director, Guardian Small Group Sales and Strategic Alliances. "With our enhancements, small business owners now have more choices that will help them to not only reduce costs, but also make their benefits relevant to their unique needs."

Additional enhancements for companies with two to nine employees include:

* Increased range of lifetime deductibles

* Optional coverage for posterior composites

* Optional in-network only plans to reduce plan holder costs (available in

allowed states)

* Availability of variable coinsurance for indemnity, NAP and value plans

* Liberalized participation requirements

And for companies with five to nine employees:

* More coverage limits on orthodontia work

* Elimination of 12 month deferment requirement on major and periodontal

work, giving members access to coverage sooner

"Dental insurance is a popular and relatively low cost benefit," said Jim Pogue, Vice President, Guardi
'/>"/>

SOURCE The Guardian Life Insurance Company of America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Guardians Dental Network Experiences Double-Digit Growth
2. Guardian Introduces New Program to Help Employers Control Health Care Premiums
3. Guardian of genome predicts treatment outcomes for childhood cancer
4. Evolution of human genomes guardian gives people unique protections from DNA damage
5. Target Data Research Sponsors Forgotten Citizens Who Are in Need of Public Guardianship To Support and Manage Their Healthcare and Personal Needs
6. Home Guardian Releases Innovative Sensor System to Keep Seniors Safe
7. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
8. Rohm and Haas Expands in India
9. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
10. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
11. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Though the number of jobs created i... companies reported a different kind of slowdown: ...s months. , Seattle, WA (...created in the medical field slowed in June overal...ind of slowdown that will be music to the ears of ...
(Date:7/25/2008)... supporting the US Department of Defense and Feder... Phoenix. Operation Golden Phoenix is a, four-da...ned to assist, federal, state and local agencies w...os. Dataline is providing a vital, ad-hoc, secure ... use during the exercise., NORFOLK, Va., July 25 ...
(Date:7/25/2008)...elationship Based on Significant Improvements in M...MDdatacor, Inc., a leader in health,care quality m..., today,announced it has entered into a long-term ...rt Wellmark,s Collaboration on Quality(SM) Incent ...ion between Wellmark and,primary care clinicians t...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...V and AIDS in India says that women and children a...the most likely one to be withdrawn// from school ...h AIDS. The National AIDS Control Organisation (NA...llion of the 5.2 million HIV/AIDS cases in India i...
... recently been developed by scientists. This appro...many malignancies before// they turn dangerous. Th... they have applied this technique to detect leukem...atic approach to diagnosing cancer at the molecula...
...researchers at the MassGeneral Institute for Neuro...bitor of an enzyme known as Poly //(ADP-ribose) po...untington’s disease affected cells from undergoing...rugs can be developed to treat Huntington's diseas...
...launched an International Stem Cell Research Insti...em cell research. // The academic medical center a...lopmental geneticist Nissim Benvenisty, M.D., Ph.D...g with David I. Meyer, Ph.D., vice president of Re...
Other Medicine News:Health News:New Technique To Diagnose Cancer At Molecular Level 2Health News:Targeting PARP1 Is Effective In Protecting HD Cells from Damage 2Health News:Center Launches New International Stem Cell Research Institute 2
(Date:7/22/2008)...pment Initiative bring MJFF,s,current active indus...,2009, NEW YORK, July 22 /PRNewswire-USNewswire/...ansformative treatments and a cure for Parkinson,s...son,s Research has awarded,$2.7 million in total f...were granted under MJFF,s Therapeutics Development...
(Date:7/22/2008)...acy of Treating Patients with ...GIN-SI, South Korea, July 22 /-,Jenne... and its South,Korean partner Green Cross Corp., a...clinical trial of its first-in-class lead product ...rated and resulted in clear,anti-cancer efficacy i...
(Date:7/22/2008)...dra(R) Resulted in Significant, Reductions in A1C ...orithm Used, BRI...om the "Adjust to,Target in Type 2 Diabetes: Compa...ng for Adjustment of Mealtime Insulin Glulisine" s...ciation,s (ADA) medical journal,Diabetes Care. Th...
(Date:7/22/2008)...RNewswire/ -- Hyperion,Therapeutics, Inc. today an...n its Phase 1/2 clinical trial to evaluate the saf...f HPN-100 (formally called GT4P) versus,BUPHENYL(R...cle disorders,(UCD). The company plans to announce...ar., (Logo: http://www.newscom.com/cgi-bin/prnh/...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 1GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 2GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 3St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 1St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 1Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 3Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 4Pharmaxis to Apply to Market Bronchitol in Australia 3283 1Pharmaxis to Apply to Market Bronchitol in Australia 3283 2Pharmaxis to Apply to Market Bronchitol in Australia 3283 3
...n three investigational,agents (VEGF Trap, S-1 and...SCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNe...y that a total of 375 abstracts,indicative of its ...d Annual Meeting of the American Society of Clinic... 2007). The results from key,studies involving the...
...INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today...of INNO-406, an orally bioavailable dual Bcr-Abl a...r,treatment-intolerant chronic myelogenous leukemi...of Clinical Oncology Annual,Meeting. The meeting t...hicago, Illinois., Information related to the pres...
Other Medicine Technology:Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: